Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

NCT00123942 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class

Stopped After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.

Conditions

Interventions

Sponsor

MedImmune LLC